logo

[breadcrumb_custom]

XFOR Stock: A Comprehensive Analysis and Forecast

In terms of market performance, X4 Pharmaceuticals Inc had a fairly even. The highest value for the stock in the past year was $2.58 on 06/13/23, and the lowest value was recorded at $0.57 on 12/12/23.

52-week price history of XFOR Stock

A stock’s 52-week high and low prices can reveal much about its current status and future trajectory. X4 Pharmaceuticals Inc’s current trading price is -41.71% away from its 52-week high, while its distance from the 52-week low is 162.28%. The stock’s price range during this period has spanned from $0.57 to $2.58. In the Healthcare sector, the X4 Pharmaceuticals Inc’s shares surpassed a trading volume of approximately 3.2 million for the day, which was noticeably higher compared to the average daily volume of 9.2.01 million over the past three months.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Market Capitalization and Financial Performance: An In-Depth Look

X4 Pharmaceuticals Inc (XFOR) has experienced a quarterly rise of 70.14% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 252.08M and boasts a workforce of 93 employees.

Making Sense of Trading Volume and Moving Average Data

Based on Barchart.com data, the company’s moving average over the 100-day period was 0.8868, with a change in price of +0.6729. Similarly, X4 Pharmaceuticals Inc recorded 2,284,065 in trading volume during the last 100 days, posting a change of +82.86%.

Examining XFOR’s Debt-to-Equity Ratio: What You Need to Know

The debt-to-equity (D/E) ratio is a crucial measure that sheds light on a company’s financial health and market standing. It is determined by dividing a company’s overall liabilities by its shareholders’ equity, showing the extent of a company’s debt usage in financing its assets compared to the shareholders’ equity. At the time of writing, the total D/E ratio for XFOR stands at 1.14. Similarly, the long-term debt-to-equity ratio is also 1.12.

XFOR Stock Stochastic Average

Today’s raw stochastic average for X4 Pharmaceuticals Inc over the last 50 days is 87.22%.This indicates a increase from the raw stochastic average of the past 20 days, which was 85.26%. Moreover, the company’s Stochastic %K and %D values for the last 20 days were 77.56% and 75.00%, respectively.

XFOR Stock Price Performance Analysis

Investors’ outlook regarding the stock price performance over the year has been a mixed bag, with a range of optimism to pessimism depending on their perspective. The index has shown a price gain of 79.01% this year. Over the last six months, there has been a weaker performance of 51.74%. The price of XFOR fallen by 54.20% during the last 30 days period. For the last 5-days stocks have improved 3.52%.

On Key

Related Posts